Patents Assigned to Micromet AG
-
Patent number: 8840888Abstract: Provided herein is a method for assessing the risk of potential adverse effects for a human patient mediated by the administration of a CD19.times.CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient.Type: GrantFiled: October 27, 2010Date of Patent: September 23, 2014Assignee: Micromet AGInventors: Dirk Nagorsen, Peter Kufer, Gerhard Zugmaier, Patrick Baeuerle
-
Publication number: 20140242081Abstract: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.Type: ApplicationFiled: July 18, 2011Publication date: August 28, 2014Applicants: MICROMET AG, MEDIMMUNE, LLCInventors: Scott Hammond, Patricia Ryan, Song Ren, Petra Lutterbuese, Maria Amann
-
Patent number: 8394926Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.Type: GrantFiled: December 21, 2006Date of Patent: March 12, 2013Assignee: Micromet AGInventors: Ralf Lutterbüse, Petra Mayer, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
-
Patent number: 8247194Abstract: The invention relates to methods of preparing antibody fragments. The invention further relates to antibody fragments prepared by said methods. The invention further relates to antibody variable regions comprised in antibody fragments producible by said methods.Type: GrantFiled: May 4, 2005Date of Patent: August 21, 2012Assignee: Micromet AGInventors: Tobias Raum, Julia Henckel, Eva Krinner, Silke Mittelstrass, Andreas Wolf
-
Patent number: 8236308Abstract: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.Type: GrantFiled: October 10, 2006Date of Patent: August 7, 2012Assignee: Micromet AGInventors: Roman Kischel, Tobias Raum, Bernd Schlereth, Doris Rau, Ronny Cierpka, Peter Kufer
-
Patent number: 8101722Abstract: The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors.Type: GrantFiled: February 16, 2005Date of Patent: January 24, 2012Assignee: Micromet AGInventors: Peter Kufer, Ulla Lenkkeri-Schütz, Ralf Lutterbüse, Birgit Kohleisen
-
Publication number: 20120009195Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.Type: ApplicationFiled: August 4, 2011Publication date: January 12, 2012Applicant: MICROMET AGInventors: TOBIAS RAUM, JULIA HEPP (NEE HENCKEL), EVA VIESER (NEE KRINNER, SILKE PETSCH (NEE MITTELSTRASS), STEVEN ZEMAN, ANDREAS WOLF, SANDRA BRUCKMAIER
-
Publication number: 20120009204Abstract: The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Applicant: MICROMET AGInventors: Carsten Reinhardt, Robert Saller
-
Patent number: 8076459Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.Type: GrantFiled: October 15, 2004Date of Patent: December 13, 2011Assignee: Micromet AGInventors: Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
-
Patent number: 8017748Abstract: The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.Type: GrantFiled: April 18, 2006Date of Patent: September 13, 2011Assignee: Micromet AGInventors: Tobias Raum, Julia Hepp (Nee Henckel), Eva Vieser (Nee Krinner), Silke Petsch (Nee Mittelstrass), Steven Zeman, Andreas Wolf, Sandra Bruckmaier
-
Patent number: 8007796Abstract: The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.Type: GrantFiled: November 29, 2006Date of Patent: August 30, 2011Assignee: Micromet AGInventors: Patrick Baeuerle, Peter Kufer, Matthias Klinger, Eugen Leo
-
Patent number: 7976842Abstract: The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.Type: GrantFiled: February 9, 2007Date of Patent: July 12, 2011Assignee: Micromet AGInventors: Carsten Reinhardt, Robert Saller
-
Patent number: 7964707Abstract: The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.Type: GrantFiled: May 31, 2006Date of Patent: June 21, 2011Assignee: Micromet AGInventors: Patrick Bäuerle, John Lumsden, Stefan Pflanz, Tobias Raum, Jörg Volkland
-
Publication number: 20110104172Abstract: The invention relates to a method for the treatment of an inflammatory disease in a subject suffering from the inflammatory disease, the method comprising the administration to said subject of a compound neutralizing GM-CSF; and a compound neutralizing IL-17.Type: ApplicationFiled: April 28, 2009Publication date: May 5, 2011Applicant: Micromet AGInventor: Christine Plater-Zyberk
-
Patent number: 7919089Abstract: The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.Type: GrantFiled: May 26, 2004Date of Patent: April 5, 2011Assignee: Micromet AGInventors: Peter Kufer, Meera Berry, Sonja Offner, Klaus Brischwein, Andreas Wolf, Tobias Raum, Birgit Kohleisen, Ulla Lenkkeri-Schutz, Patrick Baeuerle
-
Patent number: 7820166Abstract: The present invention relates to a polypeptide construct comprising at least one CDR3 region, wherein at least one of the at least CDR3 regions comprises at least one substitution in the amino acid sequence YYDDHY (SEQ ID NO.1) and wherein the at least one substitution comprises: in the first position of SEQ ID NO.1 a substitution from Y to H; in the second position of SEQ ID NO. 1 a substitution from Y to S, from Y to N, from Y to F or from Y to H; in third position of SEQ ID NO. 1 a substitution from D to N or from D to E; in the forth position of SEQ ID NO. 1 a substitution from D to Q, from D to A, from D to V, from D to E or from D to G; in the fifth position of SEQ ID NO. 1 a substitution from H to Q, from H to P, from H to Y, from H to R or from H to N; or in the sixth position a substitution from Y to N.Type: GrantFiled: October 10, 2003Date of Patent: October 26, 2010Assignee: Micromet AGInventor: Antonio Lanzavecchia
-
Publication number: 20100183615Abstract: The present invention relates to a polypeptide comprising a first human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.Type: ApplicationFiled: April 3, 2008Publication date: July 22, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Publication number: 20100150918Abstract: The present invention relates to a polypeptide comprising a human binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 (epsilon) chain as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide. In a further aspect the invention provides a method for the identification of polypeptides comprising a cross-species specific binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3? (CD3 epsilon).Type: ApplicationFiled: April 3, 2008Publication date: June 17, 2010Applicant: MICROMET AGInventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbuese, Patrick Hoffmann, Matthias Klinger, Doris Rau, Susanne Mangold
-
Patent number: 7635472Abstract: The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.Type: GrantFiled: May 26, 2004Date of Patent: December 22, 2009Assignee: Micromet AGInventors: Peter Kufer, Ralf Lutterbuse, Birgit Kohleisen, Steven Zeman, Patrick Bauerle
-
Patent number: 7632925Abstract: The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.Type: GrantFiled: September 24, 2007Date of Patent: December 15, 2009Assignee: Micromet AGInventors: Peter Kufer, Tobias Raum